TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
DNLI

Denali Therapeutics Inc

Healthcare · Biotechnology

20.50$ +3.8% vs. previous close Closing price · As of: Sep 21, 2026

Statements

Income Statement

Denali Therapeutics Inc (DNLI) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 3.6 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement DNLI
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
1.3 -305 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 3.6
90 2.2 2.2 1.9 3.0 102 2.9 2.8 0.1 108
1.3 -307 -2.2 -1.9 -3.0 -102 -2.9 -2.8 3.5 -104
90 108 107 91 98 100 116 103 102 98 104 97 401
25 25 25 25 25 30 29 32 35 39 34 36 145
115 133 118 117 123 130 146 135 137 134 135 134 540
-114 -133 -118 -117 -123 -130 -146 -135 -137 -137 -137 -131 -543
21
-99 -119 -102 -99 -107 -115 -133 -124 -127 -128 -128 -128 -511
2.3 0.0 2.1 0.1 0.1
-99 -119 -102 -99 -107 -115 -133 -124 -127 -129 -128 -128 -511
-97 -117 -130 -97 -105 -112 -130 -120 -123 -125 -126 -124 -497

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?